Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: While healthy controls had low TK serum levels (median 2.5 U/l, 95th percentile 8.8 U/l), they were significantly higher in patients with lung cancer (median 4.2 U/l, p=0.014) and also in patients with benign lung diseases (median 5.7 U/l; p=0.002). Patients with lung cancer and benign lung diseases could not be separated by TK values. No noticeable difference of TK concentrations was further found in NSCLC (median 4.3 U/l) as compared with SCLC patients (median 3.7 U/l) neither in adeno cell carcinomas (median 5.4 U/l) and squamous cell carcinomas (median 3.0 U/l). In NSCLC, the best diagnostic capacity versus benign lung diseases was found for CYFRA 21-1 (AUC 88.2%), NSE (AUC 86.4%), and CEA (AUC 82.9%), while TK reached only an AUC of 45.7%. The best diagnostic profile in SCLC versus benign lung diseases was observed for NSE (AUC 93.9%) and ProGRP (AUC 85.4%), while TK did not have any diagnostic power (AUC 46.6%). Concerning therapy monitoring, TK was unable to discriminate between the various response groups, neither pretherapeutically, nor before therapy cycles 2 and 3. However, pretherapeutic TK levels showed high prognostic value for overall survival in NSCLC patients: While median survival in patients with TK levels >or=20 U/l was only 3.1 months, it was 9.0 months in patients with TK levels <20 U/l. In multivariate analyses, TK remained an independent prognostic marker, along with the clinical variables stage and performance score. CONCLUSION: Although the performance of serum TK for diagnosis and therapy monitoring of advanced lung cancer was poor, it has a promising prognostic relevance which will have to be further validated.
|
Authors | Stefan Holdenrieder, Joachim Von Pawel, Thomas Duell, Knut Feldmann, Hannelore Raith, Annette Schollen, Dorothea Nagel, Petra Stieber |
Journal | Anticancer research
(Anticancer Res)
Vol. 30
Issue 5
Pg. 1855-62
(May 2010)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 20592392
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Carcinoembryonic Antigen
- Keratin-19
- Phosphopyruvate Hydratase
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- Carcinoembryonic Antigen
(metabolism)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, enzymology, therapy)
- Case-Control Studies
- Female
- Humans
- Keratin-19
(biosynthesis)
- Lung Neoplasms
(diagnosis, enzymology, therapy)
- Male
- Middle Aged
- Phosphopyruvate Hydratase
(metabolism)
- Prognosis
- Radioimmunoassay
- Treatment Outcome
|